These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 26107752)

  • 21. Clinical review of a long-acting, injectable formulation of risperidone.
    Knox ED; Stimmel GL
    Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
    Gastpar M; Masiak M; Latif MA; Frazzingaro S; Medori R; Lombertie ER
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):32-8. PubMed ID: 16144784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.
    Emsley R; Oosthuizen PP; Koen L; Niehaus DJ; Martinez G
    J Clin Psychiatry; 2012 Apr; 73(4):e541-7. PubMed ID: 22579160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Jockers-Scherübl MC; Kühn KU; Lemke M; Bechdolf A; Bender S; Degner D; Schlösser R; Schmidt LG; Schmitt A; Jäger M; Buchkremer G; Falkai P; Klingberg S; Köpcke W; Maier W; Häfner H; Ohmann C; Salize HJ; Schneider F; Möller HJ;
    J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.
    Malla A; Chue P; Jordan G; Stip E; Koczerginski D; Milliken H; Joseph A; Williams R; Adams B; Manchanda R; Oyewumi K; Roy MA
    Clin Schizophr Relat Psychoses; 2016; 9(4):198-208. PubMed ID: 23773886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
    Simpson GM; Mahmoud RA; Lasser RA; Kujawa M; Bossie CA; Turkoz I; Rodriguez S; Gharabawi GM
    J Clin Psychiatry; 2006 Aug; 67(8):1194-203. PubMed ID: 16965196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
    Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
    Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
    De la Gándara J; San Molina L; Rubio G; Rodriguez-Morales A; Hidalgo Borrajo R; Burón JA
    Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
    Schmauss M; Sacchetti E; Kahn JP; Medori R
    Int Clin Psychopharmacol; 2007 Mar; 22(2):85-92. PubMed ID: 17293708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.
    Martin SD; Libretto SE; Pratt DJ; Brewin JS; Huq ZU; Saleh BT
    Curr Med Res Opin; 2003; 19(4):298-305. PubMed ID: 12841922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting injectable antipsychotics: evidence of effectiveness and use.
    Manchanda R; Chue P; Malla A; Tibbo P; Roy MA; Williams R; Iyer S; Lutgens D; Banks N
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):5S-13S. PubMed ID: 23945067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
    Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
    Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.
    Foster A; Buckley P; Lauriello J; Looney S; Schooler N
    J Clin Psychopharmacol; 2017 Oct; 37(5):595-599. PubMed ID: 28806390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.
    Rubio G; Martínez I; Ponce G; Jiménez-Arriero MA; López-Muñoz F; Alamo C
    Can J Psychiatry; 2006 Jul; 51(8):531-9. PubMed ID: 16933590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
    Uchida H; Mamo DC; Kapur S; Labelle A; Shammi C; Mannaert EJ; Mann SW; Remington G
    J Clin Psychiatry; 2008 Aug; 69(8):1281-6. PubMed ID: 18642974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.